The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease ...

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

Pfizer's RSV shot Abrysvo was cleared by the FDA last October for the 18 to 59 age group, extending its 2023 approval in the ...

After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.